-
1 week ago | 
insideprecisionmedicine.com | Malorye Allison Branca
“A world-first” clinical trial targeting currently undruggable cancers will begin later this year led by a research team from The Australian National University (ANU) and Canberra Health Services. The trial targets MYC-driven cancers—including prostate, breast, ovarian, and hematological malignancies. MYC is a key regulator of cell growth. The drug being tested is PMR-116.
-
2 weeks ago | 
insideprecisionmedicine.com | Malorye Allison Branca
Microplastics (MPs), we are learning, are everywhere and implicated in a growing number of cancers. Now, a Chinese team has new evidence that they cause colorectal cancer (CRC). This study identified MPs in both peritumoral and tumor tissues of colorectal cancer patients, highlighting their accumulation in human cancers. Previous research has shown MP accumulation in other human organs, such as the lungs and liver.
-
3 weeks ago | 
insideprecisionmedicine.com | Malorye Allison Branca
The startling rise in colorectal cancer (CRC) among younger people has led to an intensive search for a cause of this trend. A new study led by researchers from the German Cancer Research Center (DKFZ) suggests alcohol consumption and smoking are significant risk factors for early-onset CRC (EOCRC). The authors say awareness about this link should be part of prevention efforts. The report appears in Clinical Colorectal Cancer and the lead author is Janine Wieser of the DKFZ.
-
1 month ago | 
insideprecisionmedicine.com | Malorye Allison Branca
The case of a sperm donor who was later found to be carrying a previously undocumented cancer-causing variant has sparked discussion about further regulating gamete donation in Europe. The donor is apparently in good health, but his biological children are at risk of Li-Fraumeni syndrome, which heightens cancer risk. Of 67 children from 46 families in eight European countries, the variant was found in 23 and cancer found in 10, to date.
-
1 month ago | 
insideprecisionmedicine.com | Malorye Allison Branca
An ultra-rapid method of genetically diagnosing brain tumors has been developed by scientists at the University of Nottingham and clinicians at Nottingham University Hospitals NHS Trust (NUH). Their approach, could cut the time it takes to classify brain tumors to as little as two hours, where it typically takes from 6-8 weeks. The groundbreaking technique is detailed in a new study published yesterday in Neuro-Oncology.
-
1 month ago | 
insideprecisionmedicine.com | Malorye Allison Branca
Most oncologists are seeing more advanced cancers and think screening barriers are the leading cause of this trend, according to a new report based on a survey conducted by the Harris Poll on behalf of Quest Diagnostics. The survey also found that 94% of oncologists thought circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing could reduce diagnosis delays in cancer recurrence. But they anticipated significant hurdles to wide adoption of this type of testing.
-
1 month ago | 
insideprecisionmedicine.com | Malorye Allison Branca
The largest study ever conducted on individuals with cardiovascular disease finds that in those with atherosclerotic cardiovascular disease (ASCVD), risk of recurrent cardiovascular events continues to rise across all ascending levels of Lp(a), with no indication of risk plateauing. This finding is contrary to earlier research. These findings were presented on May 7th at the European Atherosclerosis Society (EAS). They were simultaneously published in the European Heart Journal.
-
1 month ago | 
insideprecisionmedicine.com | Malorye Allison Branca
A team led by researchers at Mayo Clinic have used proprietary algorithms and genetic data to develop a risk score that predicts which patients are most likely to experience GI side effects from GLP-1 agonists such as Wegovy and Zepbound. Such effects impact up to 70% of patients. Nausea is the most common reason people discontinue GLP-1s. In this study, patients with certain genetic markers were more than twice as likely to experience nausea from GLP-1s compared to others (68% vs. 30%).
-
1 month ago | 
insideprecisionmedicine.com | Malorye Allison Branca
Over 7.4 million UK adults’ anonymized electronic health records were used to create two new algorithms to predict a seemingly cancer-free patient’s chances of actually having the disease. The predictive algorithms use information about a person’s health conditions and results from simple blood tests. They were developed by researchers from Queen Mary University of London and the University of Oxford.
-
1 month ago | 
insideprecisionmedicine.com | Malorye Allison Branca
Avenda Health has announced new study results showing its cancer mapping tool, Unfold AI, predicts prostate cancer spread more accurately than MRI. The study was led by Stanford and UCLA researchers. Unfold AI is the first and only FDA-approved AI-based prostate cancer decision support program. The pilot study, titled “Prediction of Seminal Vesicle Invasion Using Artificial Intelligence Prostate Cancer Risk Mapping,” was presented at the American Urological Association’s 2025 Annual Meeting.
